Mark J Beresford

Summary

Country: UK

Publications

  1. pmc Measuring proliferation in breast cancer: practicalities and applications
    Mark J Beresford
    Mount Vernon Cancer Centre, Northwood, Middlesex, UK
    Breast Cancer Res 8:216. 2006
  2. ncbi request reprint The reliability of lymph-node staging in rectal cancer after preoperative chemoradiotherapy
    M Beresford
    Mount Vernon Cancer Centre, Northwood, Middlesex, UK
    Clin Oncol (R Coll Radiol) 17:448-55. 2005
  3. doi request reprint A qualitative systematic review of the evidence base for non-cross-resistance between steroidal and non-steroidal aromatase inhibitors in metastatic breast cancer
    M Beresford
    Bristol Oncology and Haematology Centre, Horfield Road, Bristol, UK
    Clin Oncol (R Coll Radiol) 23:209-15. 2011
  4. ncbi request reprint Assessment of clinical response after two cycles of primary chemotherapy in breast cancer
    Mark J Beresford
    Mount Vernon Cancer Centre, Northwood, Middlesex, UK
    Breast Cancer Res Treat 109:337-42. 2008
  5. pmc The relationship of the neo-angiogenic marker, endoglin, with response to neoadjuvant chemotherapy in breast cancer
    M J Beresford
    Academic Oncology Unit, Mount Vernon Cancer Centre, Northwood, Middlesex, HA6 2RN, UK
    Br J Cancer 95:1683-8. 2006
  6. ncbi request reprint Neoadjuvant endocrine therapy in breast cancer
    M J Beresford
    Academic Oncology Unit, Mount Vernon Hospital, Mount Vernon Cancer Centre, Marie Curie Research Wing, Rickmansworth Road, Northwood, Middlesex, HA6 2RN, UK
    Cancer Treat Rev 33:48-57. 2007
  7. ncbi request reprint Inter- and intraobserver variability in the evaluation of dynamic breast cancer MRI
    Mark J Beresford
    Mount Vernon Cancer Centre, Northwood, United Kingdom
    J Magn Reson Imaging 24:1316-25. 2006
  8. ncbi request reprint Pre-treatment haemoglobin levels and the prediction of response to neoadjuvant chemotherapy in breast cancer
    M J Beresford
    Academic Oncology Unit, Mount Vernon Cancer Centre, Northwood, UK
    Clin Oncol (R Coll Radiol) 18:453-8. 2006
  9. ncbi request reprint Imaging of primary breast cancer with 18F-fluorodeoxythymidine PET-CT reveals heterogeneity of proliferation throughout the tumour
    Mark Beresford
    Marie Curie Research Wing, Mount Vernon Cancer Centre, Northwood, Middlesex, UK
    Eur J Nucl Med Mol Imaging 33:624. 2006
  10. ncbi request reprint Imaging breast cancer response during neoadjuvant systemic therapy
    Mark Beresford
    Mount Vernon Cancer Centre, Northwood, Middlesex, HA6 2RN, UK
    Expert Rev Anticancer Ther 5:893-905. 2005

Detail Information

Publications14

  1. pmc Measuring proliferation in breast cancer: practicalities and applications
    Mark J Beresford
    Mount Vernon Cancer Centre, Northwood, Middlesex, UK
    Breast Cancer Res 8:216. 2006
    ..The potential clinical applications of proliferative indices are discussed, including their use as prognostic indicators and predictors of response to systemic therapy...
  2. ncbi request reprint The reliability of lymph-node staging in rectal cancer after preoperative chemoradiotherapy
    M Beresford
    Mount Vernon Cancer Centre, Northwood, Middlesex, UK
    Clin Oncol (R Coll Radiol) 17:448-55. 2005
    ..To determine the prognostic significance of the nodal stage and number of nodes recovered in the surgical specimen after preoperative synchronous chemoradiation (SCRT) and surgery for locally advanced or unresectable rectal cancer...
  3. doi request reprint A qualitative systematic review of the evidence base for non-cross-resistance between steroidal and non-steroidal aromatase inhibitors in metastatic breast cancer
    M Beresford
    Bristol Oncology and Haematology Centre, Horfield Road, Bristol, UK
    Clin Oncol (R Coll Radiol) 23:209-15. 2011
    ..A systematic review was undertaken to assess the use of SAIs and NSAIs in metastatic breast cancer...
  4. ncbi request reprint Assessment of clinical response after two cycles of primary chemotherapy in breast cancer
    Mark J Beresford
    Mount Vernon Cancer Centre, Northwood, Middlesex, UK
    Breast Cancer Res Treat 109:337-42. 2008
    ..Various imaging and immunological techniques have been tested as predictors of response early in the course of chemotherapy, but their predictive value has not been compared with that of a simple early clinical assessment...
  5. pmc The relationship of the neo-angiogenic marker, endoglin, with response to neoadjuvant chemotherapy in breast cancer
    M J Beresford
    Academic Oncology Unit, Mount Vernon Cancer Centre, Northwood, Middlesex, HA6 2RN, UK
    Br J Cancer 95:1683-8. 2006
    ..Patients with high baseline new vessel counts or increased counts after conventional therapy may benefit from additional antiangiogenic therapy...
  6. ncbi request reprint Neoadjuvant endocrine therapy in breast cancer
    M J Beresford
    Academic Oncology Unit, Mount Vernon Hospital, Mount Vernon Cancer Centre, Marie Curie Research Wing, Rickmansworth Road, Northwood, Middlesex, HA6 2RN, UK
    Cancer Treat Rev 33:48-57. 2007
    ....
  7. ncbi request reprint Inter- and intraobserver variability in the evaluation of dynamic breast cancer MRI
    Mark J Beresford
    Mount Vernon Cancer Centre, Northwood, United Kingdom
    J Magn Reson Imaging 24:1316-25. 2006
    ..To quantify variations within and between observers ascribable to manual region of interest (ROI) placement in patients with breast cancer undergoing dynamic MRI...
  8. ncbi request reprint Pre-treatment haemoglobin levels and the prediction of response to neoadjuvant chemotherapy in breast cancer
    M J Beresford
    Academic Oncology Unit, Mount Vernon Cancer Centre, Northwood, UK
    Clin Oncol (R Coll Radiol) 18:453-8. 2006
    ..The purpose of this study was to assess the influence of baseline haemoglobin levels on the response to neoadjuvant chemotherapy for breast cancer...
  9. ncbi request reprint Imaging of primary breast cancer with 18F-fluorodeoxythymidine PET-CT reveals heterogeneity of proliferation throughout the tumour
    Mark Beresford
    Marie Curie Research Wing, Mount Vernon Cancer Centre, Northwood, Middlesex, UK
    Eur J Nucl Med Mol Imaging 33:624. 2006
  10. ncbi request reprint Imaging breast cancer response during neoadjuvant systemic therapy
    Mark Beresford
    Mount Vernon Cancer Centre, Northwood, Middlesex, HA6 2RN, UK
    Expert Rev Anticancer Ther 5:893-905. 2005
    ..These techniques measure changes in tumor vasculature, metabolism or proliferation and may prove to be earlier and more sensitive measures of response to systemic therapy, thus enabling tailoring of an individual's treatment...
  11. doi request reprint Primary human breast adenocarcinoma: imaging and histologic correlates of intrinsic susceptibility-weighted MR imaging before and during chemotherapy
    Sonia P Li
    Academic Oncology Unit, Mount Vernon Cancer Centre, Rickmansworth Rd, Northwood, Middlesex HA6 2RN, England
    Radiology 257:643-52. 2010
    ....
  12. doi request reprint Use of dynamic contrast-enhanced MR imaging to predict survival in patients with primary breast cancer undergoing neoadjuvant chemotherapy
    Sonia P Li
    Academic Oncology Unit, Mount Vernon Cancer Centre, Rickmansworth Rd, Northwood, Middlesex, HA6 2RN, England
    Radiology 260:68-78. 2011
    ....
  13. doi request reprint Vascular characterisation of triple negative breast carcinomas using dynamic MRI
    Sonia P Li
    Academic Oncology Unit, Mount Vernon Cancer Centre, Northwood, Middlesex HA62RN, UK
    Eur Radiol 21:1364-73. 2011
    ....
  14. ncbi request reprint Serial integrated (18)F-fluorodeoxythymidine PET/CT monitoring neoadjuvant chemotherapeutic response in invasive ductal carcinoma
    Mark Beresford
    Marie Curie Research Wing, Mount Vernon Cancer Centre, Northwood, Middlesex, UK
    Breast J 13:424-5. 2007